Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated malignant phenotypes of bladder cancer

Area of Science:

• Genomics
• Molecular Biology
• Cancer Research

Background:

• Long non-coding RNAs (lncRNAs) like UCA1 are increasingly recognized as key players in cancer progression.
• Urothelial carcinoma-associated 1 (UCA1) is upregulated in bladder cancer, promoting tumor growth and malignancy.
• Current therapeutic strategies for bladder cancer require more targeted and effective interventions.

Purpose of the Study:

• To investigate the efficacy of CRISPR/Cas9 gene editing in down-modulating UCA1 expression in bladder cancer.
• To explore the functional impact of UCA1 inhibition on bladder cancer cell proliferation, migration, and invasion.
• To evaluate the potential of urinary UCA1 as a non-invasive biomarker for bladder cancer diagnosis.

Main Methods:

• Design and construction of CRISPR/Cas9 systems targeting the UCA1 lncRNA.
• Transfection of CRISPR/Cas9-UCA1 constructs into bladder cancer cell lines (5637 and T24).
• Assessment of UCA1 expression levels, cell proliferation, migration, invasion, cell cycle, apoptosis, and MMP activity in vitro and in vivo.
• Meta-analysis of existing studies on urinary UCA1 as a diagnostic marker.

Main Results:

• CRISPR/Cas9-UCA1 systems significantly inhibited UCA1 expression in bladder cancer cells.
• Targeted UCA1 knockdown led to reduced cell proliferation, migration, and invasion.
• Mechanistically, UCA1 inhibition induced G1 cell cycle arrest, increased apoptosis, and modulated MMP activity.
• Urinary UCA1 demonstrated potential as a non-invasive diagnostic marker for bladder cancer.

Conclusions:

• CRISPR/Cas9 technology offers a viable approach for targeting and down-regulating lncRNA expression in cancer.
• Inhibiting UCA1 expression via CRISPR/Cas9 effectively suppresses bladder cancer progression.
• Urinary UCA1 holds promise as a valuable non-invasive biomarker for the early detection of bladder cancer.